What is the current stock price of Intellia Therapeutics, Inc. (NTLA)?

As of the latest market data, Intellia Therapeutics, Inc. (NTLA) is trading at $13.44. The stock has seen a gain of 6.58% today.

Does Intellia Therapeutics, Inc. (NTLA) pay a dividend?

Based on current data, Intellia Therapeutics, Inc. does not have a confirmed active dividend policy.

What is the market cap of Intellia Therapeutics, Inc.?

The current market capitalization of Intellia Therapeutics, Inc. (NTLA) is approximately unavailable.

NTLA

Intellia Therapeutics, Inc.·Healthcare

13.44

6.582%(+0.83)

Close Price

13.54

0.744%(+0.10)

Pre-Market

Last Updated: — ET

52W L: $6.8352W H: $28.25

NTLA NEWS

zacks.com

12h ago

ADMA vs Intellia Therapeutics: Which Biotech Stock Is a Better Pick Now?

NTLA gains momentum after positive phase III data for its CRISPR therapy, while ADMA faces pricing and inventory pressure in IG markets.

zacks.com

May 19

Can Intellia's Pipeline Push Drive Long-Term Growth Amid Rivalry?

NTLA advances late-stage studies for nex-z and starts FDA filing for lonvo-z, positioning its pipeline for potential long-term growth.

seekingalpha.com

May 12

Intellia Therapeutics, Inc. (NTLA) Presents at Bank of America Global Healthcare Conference 2026 Transcript

zacks.com

May 12

NTLA Q1 Earnings Beat Estimates, Revenues Miss Mark, Pipeline in Focus

Intellia cuts its Q1 loss, advances late-stage gene-editing programs and plans a 2027 launch for lonvo-z after strong phase III HAE data.

zacks.com

May 11

Intellia Therapeutics, Inc. (NTLA) Reports Q1 Loss, Misses Revenue Estimates

Intellia Therapeutics, Inc. (NTLA) came out with a quarterly loss of $0.81 per share versus the Zacks Consensus Estimate of a loss of $0.92. This compares to a loss of $1.1 per share a year ago.

globenewswire.com

May 11

Intellia Therapeutics Announces First Quarter 2026 Financial Results and Business Updates

CAMBRIDGE, Mass., May 11, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today reported business updates and financial results for the first quarter ended March 31, 2026.

Company Profile

Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemophilia A and hemophilia B, hyperoxaluria Type 1, and alpha-1 antitrypsin deficiency. Its ex vivo pipeline includes NTLA-5001 for the treatment of acute myeloid leukemia; and proprietary programs focused on developing engineered cell therapies to treat various oncological and autoimmune disorders. In addition, it offers tools comprising of Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. Intellia Therapeutics, Inc. has license and collaboration agreements with Novartis Institutes for BioMedical Research, Inc. to engineer hematopoietic stem cells for the treatment of sickle cell disease; Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; Ospedale San Raffaele; and a strategic collaboration with SparingVision SAS to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases. The company was formerly known as AZRN, Inc. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

Sector

Healthcare

Industry

Biotechnology

Employees

403

IPO Date

2016-05-06

Beta

1.93

Websitewww.intelliatx.com↗